These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 17664314)
1. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Homma T; Hori T; Sugimori G; Yamano Y Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314 [TBL] [Abstract][Full Text] [Related]
2. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Allen GP; Kaatz GW; Rybak MJ Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526 [TBL] [Abstract][Full Text] [Related]
3. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Odenholt I; Cars O J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. Deryke CA; Du X; Nicolau DP J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688 [TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743 [TBL] [Abstract][Full Text] [Related]
7. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762 [TBL] [Abstract][Full Text] [Related]
8. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158 [TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Schafer J; Hovde LB; Simonson D; Rotschafer JC Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998 [TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740 [TBL] [Abstract][Full Text] [Related]
11. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics. Smith HJ; Noreddin AM; Siemens CG; Schurek KN; Greisman J; Hoban CJ; Hoban DJ; Zhanel GG Antimicrob Agents Chemother; 2004 Sep; 48(9):3630-5. PubMed ID: 15328145 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522 [TBL] [Abstract][Full Text] [Related]
13. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363 [TBL] [Abstract][Full Text] [Related]
14. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458 [TBL] [Abstract][Full Text] [Related]
15. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Allen GP; Kaatz GW; Rybak MJ Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314 [TBL] [Abstract][Full Text] [Related]
16. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144 [TBL] [Abstract][Full Text] [Related]
17. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones. Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F; Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462 [TBL] [Abstract][Full Text] [Related]
18. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones. Blondeau JM; Blondeau LD; Hesje C; Borsos S J Chemother; 2006 Aug; 18(4):366-72. PubMed ID: 17024791 [TBL] [Abstract][Full Text] [Related]
19. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci. Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781 [TBL] [Abstract][Full Text] [Related]
20. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. Bowker KE; Garvey MI; Noel AR; Tomaselli SG; Macgowan AP J Antimicrob Chemother; 2013 May; 68(5):1130-8. PubMed ID: 23361641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]